References
1. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society of Microbiology and Infectious Diseases. Clin Infect Dis 2011;52:e103-e120.
2. Karpman E, Kurzrock EA. Adverse reactions of nitrofurantoin, trimethoprim and sulfamethoxazole in children. J Urol 2004;172:448-453.
3. Ernaelsteen D, Williams R. Jaundice due to nitrofurantoin. Gastroenterology 1961;41:590-593.
4. Stricker BH, Blok AP, Claas FH, et al. Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases. Hepatology 1988;8:599-606.
5. Holmberg L, Boman G, Bo¨ttiger LE, et al. Adverse reactions to nitrofurantoin. Analysis of 921 reports. Am J Med 1980;69:733-738.
6. Penn RG, Griffin JP. Adverse reactions to nitrofurantoin in the United Kingdom, Sweden, and Holland. Br Med J (Clin Res Ed) 1982;284:1440-1442.
7. Bjornsson E, Talwalkar J, Treeprasertsuk S, et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology 2010;51:2040-2048.
8. Iwarson S, Lindberg J, Lundin P. Nitrofurantoin-induced chronic liver disease. Clinical course and outcome of five cases. Scand J Gastroenterol 1979;14:497-502.
9. Sharp JR, Ishak KG, Zimmerman HJ. Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin. Ann Intern Med 1980;92:14-19.
10. Klemola H, Penttila O, Runeberg L, et al. Anicteric liver damage during nitrofurantoin medication. Scand J Gastroenterol 1975;10:501-505.
11. Stromberg A, Wengle B. Chronic active hepatitis induced by nitrofurantoin. Br Med J 1976;2:174-175.
12. Mollison LC, Angus P, Richards M, et al. Hepatitis due to nitrofurantoin. Med J Aust 1992;156:347-349.
13. Amit G, Cohen P, Ackerman Z. Nitrofurantoin-induced chronic active hepatitis. Isr Med Assoc J 2002;4:184-186.
14. Galan MV, Potts JA, Silverman AL, et al. The burden of acute nonfulminant drug-induced hepatitis in a United States tertiary referral center. J Clin Gastroenterol 2005;39:64-67.
15. Appleyard S, Saraswati R, Gorard DA. Autoimmune hepatitis triggered by nitrofurantoin: a case series. J Med Case Reports 2010;4:311.
16. Coraggio MJ, Gross TP, Roscelli JD. Nitrofurantoin toxicity in children. Pediatr Infect Dis J 1989;8:163-166.
17. Cook GC, Sherlock S. Jaundice and its relation to therapeutic agents. Lancet 1965;1:175-179.
18. Jokela S. Liver disease due to nitrofurantoin. Gastroenterology 1967;53:306-311.
19. Lindberg J, Lindholm A, Lundin P, et al. Trigger factors and HL-A antigens in chronic active hepatitis. Br Med J 1975;4:77-79.
20. Fagrell B, Strandberg I, Wengle B. A nitrofurantoin-induced disorder simulating chronic active hepatitis. A case report. Acta Med Scand 1976;199:237-239.
21. Black M, Rabin L, Schatz N. Nitrofurantoin-induced chronic active hepatitis. Ann Intern Med 1980;92:62-64.
22. Engel JJ, Vogt TR, Wilson DE. Cholestatic hepatitis after administration of furan derivatives. Arch Intern Med 1975;135:733-735.
23. Hatoff DE, Cohen M, Schweigert BF, et al. Nitrofurantoin: another cause of drug-induced chronic active hepatitis? A report of a patient with HLA-B8 antigen. Am J Med 1979;67:117-121.
24. Sippel PJ, Agger WA. Nitrofurantoin-induced granulomatous hepatitis. Urology 1981;18:177-178.
25. Miller AR, Addis BJ, Clarke PD. Nitrofurantoin and chronic active hepatitis. Ann Intern Med 1982;97:452.
26. Berry WR, Warren GH, Reichen J. Nitrofurantoin-induced cholestatic hepatitis from cow’s milk in a teenaged boy. West J Med 1984;140:278-280.
27. Young TL, Achkar E, Tuthill R, et al. Chronic active hepatitis induced by nitrofurantoin. Cleve Clin Q 1985;52:253-256.
28. Burger HC, Meiring JL, Nel PJ. Chronic active hepatitis caused by nitrofurantoin: a case report. S Afr Med J 1985;67:125-126.
29. Thomson RG, James OF. Seventh-nerve palsy and hepatitis associated with nitrofurantoin. Hum Toxicol 1986;5:387-388.
30. Reinhart HH, Reinhart E, Korlipara P, et al. Combined nitrofurantoin toxicity to liver and lung. Gastroenterology 1992;102:1396-1399.
31. Hebert MF, Roberts JP. Endstage liver disease associated with nitrofurntoin requiring liver transplantation. Ann Pharmacother 1993;27:1193-1194.
32. Paiva LA, Wright PJ, Koff RS. Long-term hepatic memory for hypersensitivity to nitrofurantoin. Am J Gastroenterol 1992;87:891-893.
33. Mulberg AE, Bell LM. Fatal cholestatic hepatitis and multisystem failure associated with nitrofurantoin. J Pediatr Gastroenterol Nutr 1993;17:307-309.
34. Burgert SJ, Burke JP, Box TD. Reversible nitrofurantoin-induced chronic active hepatitis and hepatic cirrhosis in a patient awaiting liver transplantation. Transplantation 1995;59:448-449.
35. Schattner A, Von der Walde J, Kozak N, et al. Nitrofurantoin-induced immune-mediated lung and liver disease.Am J Med Sci 1999;317:336-340.
36. Edoute Y, Karmon Y, Roguin A, et al. Fatal liver necrosis associated with the use of nitrofurantoin. Isr Med Assoc J 2001;3:382-383.
37. Mackenzie FD, Storie WJ. Pulmonary and hepatic toxicity due to nitrofurantoin. J Pharm Pract Res 2004;34:134-135.
38. Peedikayil MC, Dahhan TI, Al Ashgar Hi. Nitrofurantoin-induced fulminant hepatitis mimicking autoimmune hepatitis. Ann Pharmacother 2006;40:1888-1889.
39. Kiang TK, Ford JA, Yoshida EM, et al. Nitrofurantoin-associated lung and liver toxicity leading to liver transplantation in a middle-aged patient. Can J Hosp Pharm 2011;64:262-270.
40. Koulaouzidis A, Bhat S, Moschos J, et al. Nitrofurantoin-induced lung-and hepatotoxicity. Ann Hepatol 2007;6:119-121.
41. Sargin G, Elbek O, Balantekin C, et al. Acute respiratory distress syndrome and hepatotoxicity associated with single dose nitrofurantoin use. Case Rep Pulmonol 2012;2012:465389.
42. Bjornsson ES, Bergmann OM, Bjornsson HK, et al. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013;144:1419-1425.
43. Thiim M, Friedman LS. Hepatotoxicity of antibiotics and antifungals.Clin Liver Dis 2003;7:381-399.
44. Tolman KG. Nitrofurantoin and chronic active hepatitis. Ann Intern Med 1980;92:119-120.
45. Kelly BD, Heneghan MA, Bennani F, et al. Nitrofurantoin-induced hepatotoxicity mediated by CD8+ T cells.Am J Gastroenterol1998;93:819-821.
46. Boelsterli UA, Ho HK, Zhou S, et al. Bioactivation and hepatotoxicity of nitroaromatic drugs. Curr Drug Metab 2006;7:715-727.
47. Oplinger M, Andrews CO. Nitrofurantoin contraindication in patients with a creatinine clearance below 60 mL/min: looking for the evidence. Ann Pharmacother 2013;47:106-111.